Table 3

Adverse event frequency measures and screening form performance

Cross-sectional studyRetrospective study
Positive screening review formPositive predictive
values		Prevalence of adverse eventsPositive screening review formPositive predictive valuesCumulative incidence of adverse events
Country 139.0%
926/2373
(95% CI 37.0% to 41.0%)		33.7%
312/926
(95% CI 30.6% to 36.8%)		13.1%
312/2373
(95% CI 11.8% to 14.5%)		61.7%
145/235
(95% CI 6.7% to 8.1%)		51.7%
75/145
(95% CI 43.2% to 60.2%)		31.9%
75/235
(95% CI 25.7% to 38.1%)
Country 230.6%
887/2897
(95% CI 28.9% to 32.3%)		25.3%
224/887
(95% CI 22.3% to 28.2%)		7.7%
224/2897
(95% CI 6.7% to 8.7%)		38.9%
112/288
(95% CI 33.1% to 44.7%)		32.1%
36/112
(95% CI 23.0% to 41.2%)		12.5%
36/288
(95% CI 8.5% to 16.5%)
Country 335.4%
578/1632
95% CI 33.1% to 37.8%)		34.3%
198/578
(95% CI 30.3% to 38.2%)		12.1%
198/1632
(95% CI 6.7% to 8.7%)		63.7%
107/168
(95% CI 56.1% to 71.3%)		57.0%
61/107
(95% CI 47.2% to 66.9%)		36.3%
61/168
(95% CI 28.7% to 43.9%)
Country 434.5%
692/2003
(95% CI 32.4% to 36.7%)		24.7%
171/692
(95% CI 21.4% to 27.9%)		8.5%
171/2003
(95% CI 7.3% to 9.8%)		46.9%
82/175
(95% CI 39.2% to 54.5%)		24.4%
20/82
(95% CI 14.5% to 34.3%)		11.4%
20/175
(95% CI 6.4% to 16.4%)
Country 531.1%
770/2474
(95% CI 29.3% to 32.9%)		37.1%
286/770
(95% CI 33.7% to 40.6%)		11.6%
286/2474
(95% CI 10.3% to 12.8%)		17.1%
38/222
(95% CI 11.9% to 22.3%)		60.5%
23/38
(95% CI 43.7% to 77.4%)		10.4%
23/222
(95% CI 6.1% to 14.6%)
Total33.9%
3853/11379
(95% CI 32.9% to 34.7%)		30.9%
1191/3853
(95% CI 29.4% to 32.4%)		10.5%
1191/11379
(95% CI 9.9 to 11.0)		44.5%
484/1088
(95% CI 41.5% to 47.5%)		44.4%
215/484
(95% CI 39.3% to 48.3%)		19.8%
215/1088
(95% CI 17.3% to 22.2%)